These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15951989)

  • 21. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colon cancer after infliximab therapy for Crohn's disease.
    Ferreira F; Lopes S; Macedo G
    BioDrugs; 2010 Dec; 24 Suppl 1():18-21. PubMed ID: 21175230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New therapy for orolaryngeal manifestations of Crohn's disease.
    Ottaviani F; Schindler A; Capaccio P; Petrone M; Bianchi Porro G
    Ann Otol Rhinol Laryngol; 2003 Jan; 112(1):37-9. PubMed ID: 12537056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-clinical Crohn's disease: diagnosis, treatment and six year follow-up.
    Sorrentino D; Avellini C; Geraci M; Vadalà S
    J Crohns Colitis; 2014 Jul; 8(7):702-7. PubMed ID: 24411923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP
    Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
    Rednic S; Marinescu C; Chira R; Rogojan L; Rednic N
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):379-82. PubMed ID: 17205151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease.
    Hukkinen M; Pakarinen MP; Piekkala M; Koivusalo A; Rintala R; Kolho KL
    J Crohns Colitis; 2014 Aug; 8(8):756-62. PubMed ID: 24447625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease.
    Van Assche G; Herrmann KA; Louis E; Everett SM; Colombel JF; Rahier JF; Vanbeckevoort D; Meunier P; Tolan D; Ernst O; Rutgeerts P; Vermeire S; Aerden I; Oortwijn A; Ochsenkühn T
    J Crohns Colitis; 2013 Dec; 7(12):950-7. PubMed ID: 23411006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal healing of Crohn's disease in a patient with concurrent systemic lupus erythematosus using infliximab.
    Kagaya Y; Sakamoto H; Yano T; Sunada K; Lefor AK; Niki T; Yamamoto H
    Clin J Gastroenterol; 2017 Jun; 10(3):244-249. PubMed ID: 28364315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Management of colonic Crohn disease with no response to corticoids and sulfazalazine: first case of pediatric use of infliximab in Peru].
    Muñoz Urribarri A; Sylvester F; Delgado Godos A; Castillo Durán R
    Rev Gastroenterol Peru; 2013; 33(2):162-6. PubMed ID: 23838945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease.
    Uslu N; Usta Y; Saltik-Temizel IN; Demir H; Gürakan F; Ozen H; Yüce A
    J Crohns Colitis; 2010 Feb; 4(1):106-9. PubMed ID: 21122492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.